Carl Icahn
Carl Icahn's Portfolio
| Ticker | # of Shares | Price | Value | |
|---|---|---|---|---|
| CVI | 71,198,718 | $63.64 | $4,531,086,414 | |
| NFLX | 5,541,066 | $239.00 | $1,324,314,774 | |
| CHK | 59,698,689 | $20.27 | $1,210,092,427 | |
| FRX | 30,662,005 | $38.53 | $1,181,407,053 | |
| RIG | 20,154,035 | $54.03 | $1,088,922,512 | |
| HLF | 16,966,485 | $44.44 | $753,990,594 | |
| HLF | 16,355,131 | $44.44 | $726,822,022 | |
| FDML | 76,697,804 | $8.81 | $675,707,654 | |
| NUAN | 33,899,274 | $18.62 | $631,204,482 | |
| HAIN | 7,239,963 | $66.86 | $484,063,927 | |
| View Additional Portfolio Information » | ||||
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
-
Carl Icahn Liquidates Biogen Idec (BIIB), Chesapeake Energy (CHK); Targets Oshkosh (OSK), Forest Labs (FRX) and Commercial Metals (CMC)
-
Icahn's Icahn Capital Shows New Stake in Amgen (AMGN), Clorox (CLX) and Southern Union (NYSE: SUG); Raises Dynegy (DYN), Lowers Chesapeake (CHK)
-
Icahn Hangs on to Pharmas, Makes Housing Play, Increases Lions Gate Holding in Recent 13F (MOT, MAS, HAIN, More...)
-
Morning Movers 4/17: DRYS, TEL, ICUI, MHP, TPX Higher; CYT, MGM, HNSN, MEG, AOS Lower
